Brain renin-angiotensin system in the nexus of hypertension and aging

Hypertension Research

Volumn 36, Issue 1, 2013, Pages 5-13

  Arnold, Amy C ^a   Gallagher, Patricia E ^a   Diz, Debra I ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

autonomic nervous system; brain; cardiovascular; metabolic; transgenic rats

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN[1-7]; LEPTIN; RENIN;

ADRENERGIC SYSTEM; AGING; BLOOD PRESSURE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIFESPAN; NONHUMAN; PARASYMPATHETIC FUNCTION; PRESSORECEPTOR REFLEX; PROTEIN INTERACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYMPATHETIC FUNCTION; SYSTOLIC BLOOD PRESSURE; TIGHT JUNCTION;

AGED; AGING; ANIMALS; AUTONOMIC NERVOUS SYSTEM; BRAIN; HUMANS; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM;

EID: 84872093629     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2012.161     Document Type: Review

References (124)

1. Hotta H, Uchida S. Aging of the autonomic nervous system and possible improvements in autonomic activity using somatic afferent stimulation. Geriatr Gerontol Int 2010; 10(Suppl 1): S127-S136.
2. Ferrari AU, Radaelli A, Centola M. Invited review: aging and the cardiovascular system. J Appl Physiol 2003; 95: 2591-2597.
3. Monahan KD. Effect of aging on baroreflex function in humans. Am J Physiol Regul Integr Comp Physiol 2007; 293: R3-R12.
4. McKinley MJ, Albiston AL, Allen AM, Mathai ML, May CN, McAllen RM, Oldfield BJ, Mendelsohn FA, Chai SY. The brain renin-angiotensin system: location and physiological roles. Int J Biochem Cell Biol 2003; 35: 901-918.
5. Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. J Intern Med 2008; 264: 224-236.
6. Ito M, Oliverio MI, Mannon PJ, Best CF, Maeda N, Smithies O, Coffman TM. Regulation of blood pressure by the type 1 A angiotensin II receptor gene. Proc Natl Acad Sci USA 1995; 92: 3521-3525.
7. Cole J, Ertoy D, Bernstein KE. Insights derived from ACE knockout mice. J Renin Angiotensin Aldosterone Syst 2000; 1: 137-141.
8. Catanzaro DF, Frishman WH. Angiotensin receptor blockers for management of hypertension. South Med J 2010; 103: 669-673.
9. Santos RA, Ferreira AJ, Simoes e Silva AC. Recent advances in the angiotensinconverting enzyme 2-angiotensin(1-7)-Mas axis. Exp Physiol 2008; 93: 519-527.
10. Iyer SN, Ferrario CM, Chappell MC. Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension 1998; 31(1 Pt 2): 356-361.
11. Benter IF, Ferrario CM, Morris M, Diz DI. Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive rats. Am J Physiol 1995; 269(1 Pt 2): H313-H319.
12. Benter IF, Yousif MH, Cojocel C, Al-Maghrebi M, Diz DI. Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. Am J Physiol Heart Circ Physiol 2007; 292: H666-H672.
13. Giani JF, Burghi V, Veiras LC, Tomat A, Munoz MC, Cao G, Turyn D, Toblli JE, Dominici FP. Angiotensin-(1-7) attenuates diabetic nephropathy in Zucker diabetic fatty rats. Am J Physiol Renal Physiol 2012; 302: F1606-F1615.
14. de Moura MM, dos Santos RA, Campagnole-Santos MJ, Todiras M, Bader M, Alenina N, Haibara AS. Altered cardiovascular reflexes responses in conscious Angiotensin-(1-7) receptor Mas-knockout mice. Peptides 2010; 31: 1934-1939.
15. Gurley SB, Allred A, Le TH, Griffiths R, Mao L, Philip N, Haystead TA, Donoghue M, Breitbart RE, Acton SL, Rockman HA, Coffman TM. Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J Clin Invest 2006; 116: 2218-2225.
16. Oudit GY, Kassiri Z, Patel MP, Chappell M, Butany J, Backx PH, Tsushima RG, Scholey JW, Khokha R, Penninger JM. Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc Res 2007; 75: 29-39.
17. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveira-dos-Santos AJ, da Costa J, Zhang L, Pei Y, Scholey J, Ferrario CM, Manoukian AS, Chappell MC, Backx PH, Yagil Y, Penninger JM. Angiotensin- converting enzyme 2 is an essential regulator of heart function. Nature 2002; 417: 822-828.
18. Garcia-Espinosa MA, Shaltout HA, Gallagher PE, Chappell MC, Diz DI. In Vivo Expression of Angiotensin-(1-7) Lowers Blood Pressure and Improves Baroreflex Function in Transgenic (mRen2)27 Rats. J Cardiovasc Pharmacol 2012; 60: 150-157.
19. Shaltout HA, Rose JC, Chappell MC, Diz DI. Angiotensin-(1-7) Deficiency and Baroreflex Impairment Precede the Antenatal Betamethasone Exposure-Induced Elevation in Blood Pressure. Hypertension 2012; 59: 453-458.
20. Diz DI, Garcia-Espinosa MA, Gallagher PE, Ganten D, Ferrario CM, Averill DB. Angiotensin-(1-7) and baroreflex function in nucleus tractus solitarii of (mRen2)27 transgenic rats. J Cardiovasc Pharmacol 2008; 51: 542-548.
21. Diz DI, Kasper SO, Sakima A, Ferrario CM. Aging and the brain renin-angiotensin system: insights from studies in transgenic rats. Cleve Clin J Med 2007; 74(Suppl 1): S95-S98.
22. Ferrario CM, Martell N, Yunis C, Flack JM, Chappell MC, Brosnihan KB, Dean RH, Fernandez A, Novikov SV, Pinillas C, Luque M. Characterization of angiotensin-(1-7) in the urine of normal and essential hypertensive subjects. Am J Hypertens 1998; 11: 137-146.
23. Wakahara S, Konoshita T, Mizuno S, Motomura M, Aoyama C, Makino Y, Kato N, Koni I, Miyamori I. Synergistic expression of angiotensin-converting enzyme (ACE) and ACE2 in human renal tissue and confounding effects of hypertension on the ACE to ACE2 ratio. Endocrinology 2007; 148: 2453-2457.
24. Shaltout HA, Figueroa JP, Rose JC, Diz DI, Chappell MC. Alterations in Circulatory and Renal Angiotensin-Converting Enzyme and Angiotensin-Converting Enzyme 2 in Fetal Programmed Hypertension. Hypertension 2009; 53: 404-408.
25. Shaltout HA, Westwood BM, Averill DB, Ferrario CM, Figueroa JP, Diz DI, Rose JC, Chappell MC. Angiotensin metabolism in renal proximal tubules, urine, and serum of sheep: evidence for ACE2-dependent processing of angiotensin II. Am J Physiol Renal Physiol 2007; 292: F82-F91.
26. Luther JM, Brown NJ. The renin-angiotensin-aldosterone system and glucose homeostasis. Trends Pharmacol Sci 2011; 32: 734-739.
27. Strazzullo P, Galletti F. Impact of the renin-angiotensin system on lipid and carbohydrate metabolism. Curr Opin Nephrol Hypertens 2004; 13: 325-332.
28. Giacchetti G, Faloia E, Mariniello B, Sardu C, Gatti C, Camilloni MA, Guerrieri M, Mantero F. Overexpression of the renin-angiotensin system in human visceral adipose tissue in normal and overweight subjects. Am J Hypertens 2002; 15: 381-388.
29. Hainault I, Nebout G, Turban S, Ardouin B, Ferre P, Quignard-Boulange A. Adipose tissue-specific increase in angiotensinogen expression and secretion in the obese (fa/fa) Zucker rat. Am J Physiol Endocrinol Metab 2002; 282: E59-E66.
30. Massiera F, Bloch-Faure M, Ceiler D, Murakami K, Fukamizu A, Gasc JM, Quignard-Boulange A, Negrel R, Ailhaud G, Seydoux J, Meneton P, Teboul M. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 2001; 15: 2727-2729.
31. Yvan-Charvet L, Quignard-Boulange A. Role of adipose tissue renin-angiotensin system in metabolic and inflammatory diseases associated with obesity. Kidney Int 2011; 79: 162-168.
32. Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M, Luft FC, Sharma AM. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005; 45: 356-362.
33. Strazzullo P, Iacone R, Iacoviello L, Russo O, Barba G, Russo P, D'Orazio A, Barbato A, Cappuccio FP, Farinaro E, Siani A. Genetic variation in the renin-angiotensin system and abdominal adiposity in men: the Olivetti Prospective Heart Study. Ann Intern Med 2003; 138: 17-23.
34. Chaves FJ, Giner V, Corella D, Pascual J, Marin P, Armengod ME, Redon J. Body weight changes and the A-6G polymorphism of the angiotensinogen gene. Int J Obes Relat Metab Disord 2002; 26: 1173-1178.
35. Stucchi P, Cano V, Ruiz-Gayo M, Fernandez-Alfonso MS. Aliskiren reduces bodyweight gain, adiposity and plasma leptin during diet-induced obesity. Br J Pharmacol 2009; 158: 771-778.
36. Weisinger RS, Stanley TK, Begg DP, Weisinger HS, Spark KJ, Jois M. Angiotensin converting enzyme inhibition lowers body weight and improves glucose tolerance in C57BL/6J mice maintained on a high fat diet. Physiol Behav 2009; 98: 192-197.
37. Velkoska E, Warner FJ, Cole TJ, Smith I, Morris MJ. Metabolic effects of low dose angiotensin converting enzyme inhibitor in dietary obesity in the rat. Nutr Metab Cardiovasc Dis 2010; 20: 49-55.
38. Chou CL, Lai YH, Lin TY, Lee TJ, Fang TC. Aliskiren prevents and ameliorates metabolic syndrome in fructose-fed rats. Arch Med Sci 2011; 7: 882-888.
39. Massiera F, Seydoux J, Geloen A, Quignard-Boulange A, Turban S, Saint-Marc P, Fukamizu A, Negrel R, Ailhaud G, Teboul M. Angiotensinogen- deficient mice exhibit impairment of diet-induced weight gain with alteration in adipose tissue development and increased locomotor activity. Endocrinology 2001; 142: 5220-5225.
40. Kouyama R, Suganami T, Nishida J, Tanaka M, Toyoda T, Kiso M, Chiwata T, Miyamoto Y, Yoshimasa Y, Fukamizu A, Horiuchi M, Hirata Y, Ogawa Y. Attenuation of diet-induced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin II type 1a receptor. Endocrinology 2005; 146: 3481-3489.
41. Takahashi N, Li F, Hua K, Deng J, Wang CH, Bowers RR, Bartness TJ, Kim HS, Harp JB. Increased energy expenditure, dietary fat wasting, and resistance to diet-induced obesity in mice lacking renin. Cell Metab 2007; 6: 506-512.
42. Jayasooriya AP, Mathai ML, Walker LL, Begg DP, Denton DA, Cameron-Smith D, Egan GF, McKinley MJ, Rodger PD, Sinclair AJ, Wark JD, Weisinger HS, Jois M, Weisinger RS. Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance. Proc Natl Acad Sci USA 2008; 105: 6531-6536.
43. Hershon KS. Mechanistic and clinical aspects of renin-angiotensin- aldosterone system blockade in the prevention of diabetes mellitus and cardiovascular disease. Endocr Pract 2011; 17: 430-440.
44. Cassis LA, Marshall DE, Fettinger MJ, Rosenbluth B, Lodder RA. Mechanisms contributing to angiotensin II regulation of body weight. Am J Physiol 1998; 274(5 Pt 1): E867-E876.
45. de Kloet AD, Krause EG, Scott KA, Foster MT, Herman JP, Sakai RR, Seeley RJ, Woods SC. Central angiotensin II has catabolic action at white and brown adipose tissue. Am J Physiol Endocrinol Metab 2011; 301: E1081-E1091.
46. Fliser D, Schaefer F, Schmid D, Veldhuis JD, Ritz E. Angiotensin II affects basal, pulsatile, and glucose-stimulated insulin secretion in humans. Hypertension 1997; 30: 1156-1161.
47. Fliser D, Arnold U, Kohl B, Hartung R, Ritz E. Angiotensin II enhances insulin sensitivity in healthy volunteers under euglycemic conditions. J Hypertens 1993; 11: 983-988.
48. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlof B, Devereux RB, Beevers G, de FU, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman JM, Snapinn S. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002; 20: 1879-1886.
49. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-2031.
50. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
51. Munoz MC, Giani JF, Dominici FP. Angiotensin-(1-7) stimulates the phosphorylation of Akt in rat extracardiac tissues in vivo via receptor Mas. Regul Pept 2010; 161: 1-7.
52. Santos SH, Fernandes LR, Mario EG, Ferreira AV, Porto LC, Alvarez-Leite JI, Botion LM, Bader M, Alenina N, Santos RA. Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism. Diabetes 2008; 57: 340-347.
53. Bindom SM, Lazartigues E. The sweeter side of ACE2: Physiological evidence for a role in diabetes. Mol Cell Endocrinol 2009; 302: 193-202.
54. Santos SH, Braga JF, Mario EG, Porto LC, Rodrigues-Machado MG, Murari A, Botion LM, Alenina N, Bader M, Santos RA. Improved lipid and glucose metabolism in transgenic rats with increased circulating angiotensin-(1-7). Arterioscler Thromb Vasc Biol 2010; 30: 953-961.
55. Bindom SM, Hans CP, Xia H, Boulares AH, Lazartigues E, Angiotensin IG. Ç ôConverting enzyme type 2 (ACE2) gene therapy improves glycemic control in diabetic mice. Diabetes 2010; 59: 2540-22548.
56. Feng Y, Xia H, Santos RA, Speth R, Lazartigues E. Angiotensin-converting enzyme 2: a new target for neurogenic hypertension. Exp Physiol 2010; 95: 601-606.
57. Sakima A, Averill DB, Gallagher PE, Kasper SO, Tommasi EN, Ferrario CM, Diz DI. Impaired heart rate baroreflex in older rats: role of endogenous angiotensin-(1-7) at the nucleus tractus solitarii. Hypertension 2005; 46: 333-340.
58. Itoh H, Bunag RD. Age-related reduction of reflex bradycardia in conscious rats by catecholaminergic nucleus tractus solitarius lesions. Mech Ageing Dev 1993; 67: 47-63.
59. Garcia-Espinosa MA, Shaltout HA, Olson J, Westwood BM, Robbins ME, Link K, Diz DI. Proton magnetic resonance spectroscopy detection of neurotransmitters in dorsomedial medulla correlate with spontaneous baroreceptor reflex function. Hypertension 2010; 55: 487-493.
60. Diz DI, Garcia-Espinosa MA, Shaltout HA, Olson J, Bourland JD, Groban L. Correlation of the brain medullary metabolites N-acetyl aspartic acid and N-acetyl aspartyl glutamate with the age related decline in sensitivity for baroreflex control of heart rate in humans. Hypertension 2011; 58: e116 (Abstract).
61. Thayer JF, Lane RD. The role of vagal function in the risk for cardiovascular disease and mortality. Biol Psychol 2007; 74: 224-242.
62. Kulminski AM, Culminskaya IV, Ukraintseva SV, Arbeev KG, Akushevich I, Land KC, Yashin AI. Polymorphisms in the ACE and ADRB2 genes and risks of aging-associated phenotypes: the case of myocardial infarction. Rejuvenation Res 2010; 13: 13-21.
63. Mohamed MA, Weir MR. Renin angiotensin system inhibition in the older person: a review. Clin Geriatr Med 2009; 25: 245-257.
64. Basso N, Paglia N, Stella I, de Cavanagh EM, Ferder L, del Rosario Lores AM, Inserra F. Protective effect of the inhibition of the renin-angiotensin system on aging. Regul Pept 2005; 128: 247-252.
65. Benigni A, Corna D, Zoja C, Sonzogni A, Latini R, Salio M, Conti S, Rottoli D, Longaretti L, Cassis P, Morigi M, Coffman TM, Remuzzi G. Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest 2009; 119: 524-530.
66. Modrick ML, Didion SP, Sigmund CD, Faraci FM. Role of oxidative stress and AT1 receptors in cerebral vascular dysfunction with aging. Am J Physiol Heart Circ Physiol 2009; 296: H1914-H1919.
67. Kaneko K, Ito M, Fumoto T, Fukuhara R, Ishida J, Fukamizu A, Ikeda K. Physiological function of the angiotensin AT1a receptor in bone remodeling. J Bone Miner Res 2011; 26: 2959-2966.
68. Oudit GY, Liu GC, Zhong J, Basu R, Chow FL, Zhou J, Loibner H, Janzek E, Schuster M, Penninger JM, Herzenberg AM, Kassiri Z, Scholey JW. Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes 2010; 59: 529-538.
69. Xia H, Suda S, Bindom S, Feng Y, Gurley SB, Seth D, Navar LG, Lazartigues E. ACE2-mediated reduction of oxidative stress in the central nervous system is associated with improvement of autonomic function. PLoS One 2011; 6: e22682.
70. Gilliam-Davis S, Payne VS, Kasper SO, Tommasi EN, Robbins ME, Diz DI. Long-term AT1 receptor blockade improves metabolic function and provides renoprotection in Fischer-344 rats. Am J Physiol Heart Circ Physiol 2007; 293: H1327-H1333.
71. Gilliam-Davis S, Gallagher PE, Payne VS, Kasper SO, Tommasi EN, Westwood BM, Robbins ME, Chappell MC, Diz DI. Long-term systemic angiotensin II type 1 receptor blockade regulates mRNA expression of dorsomedial medulla renin-angiotensin system components. Physiol Genomics 2011; 43: 829-835.
72. Anderson S. Ageing and the renin-angiotensin system. Nephrol Dial Transplant 1997; 12: 1093-1094.
73. Diz DI, Lewis K. Dahl memorial lecture: the renin-angiotensin system and aging. Hypertension 2008; 52: 37-43.
74. Britto RR, Santos RA, Fagundes-Moura CR, Khosla MC, Campagnole-Santos MJ. Role of angiotensin-(1-7) in the modulation of the baroreflex in renovascular hypertensive rats. Hypertension 1997; 30(3 Pt 2): 549-556.
75. Diz DI, Jessup JA, Westwood BM, Bosch SM, Vinsant S, Gallagher PE, Averill DB. Angiotensin peptides as neurotransmitters/neuromodulators in the dorsomedial medulla. Clin Exp Pharmacol Physiol 2002; 29: 473-482.
76. Dupont AG, Brouwers S. Brain angiotensin peptides regulate sympathetic tone and blood pressure. J Hypertens 2010; 28: 1599-1610.
77. Campagnole-Santos MJ, Diz DI, Ferrario CM. Baroreceptor reflex modulation by angiotensin II at the nucleus tractus solitarii. Hypertension 1988; 11(2 Pt 2): I167-I171.
78. Casto R, Phillips MI. Angiotensin II attenuates baroreflexes at nucleus tractus solitarius of rats. Am J Physiol 1986; 250(2 Pt 2): R193-R198.
79. Oliveira DR, Santos RA, Santos GF, Khosla M, Campagnole-Santos MJ. Changes in the baroreflex control of heart rate produced by central infusion of selective angiotensin antagonists in hypertensive rats. Hypertension 1996; 27: 1284-1290.
80. Chaves GZ, Caligiorne SM, Santos RA, Khosla MC, Campagnole-Santos MJ. Modulation of the baroreflex control of heart rate by angiotensin-(1-7) at the nucleus tractus solitarii of normotensive and spontaneously hypertensive rats. J Hypertens 2000; 18: 1841-1848.
81. Campagnole-Santos MJ, Diz DI, Santos RA, Khosla MC, Brosnihan KB, Ferrario CM. Cardiovascular effects of angiotensin-(1-7) injected into the dorsal medulla of rats. Am J Physiol 1989; 257(1 Pt 2): H324-H329.
82. Diz DI, Garcia-Espinosa MA, Gegick S, Tommasi EN, Ferrario CM, Ann TE, Chappell MC, Gallagher PE. Injections of angiotensin-converting enzyme 2 inhibitor MLN4760 into nucleus tractus solitarii reduce baroreceptor reflex sensitivity for heart rate control in rats. Exp Physiol 2008; 93: 694-700.
83. Ferrari AU, Daffonchio A, Albergati F, Mancia G. Differential effects of aging on the heart rate and blood pressure influences of arterial baroreceptors in awake rats. J Hypertens 1991; 9: 615-621.
84. Kasper SO, Carter CS, Ferrario CM, Ganten D, Ferder LF, Sonntag WE, Gallagher PE, Diz DI. Growth, metabolism, and blood pressure disturbances during aging in transgenic rats with altered brain renin-angiotensin systems. Physiol Genomics 2005; 23: 311-317.
85. Bachmann S, Peters J, Engler E, Ganten D, Mullins J. Transgenic rats carrying the mouse renin gene-morphological characterization of a low-renin hypertension model. Kidney Int 1992; 41: 24-36.
86. Isa K, Arnold AC, Westwood BM, Chappell MC, Diz DI. Angiotensin- converting enzyme inhibition, but not AT(1) receptor blockade, in the solitary tract nucleus improves baroreflex sensitivity in anesthetized transgenic hypertensive (mRen2)27 rats. Hypertens Res 2011; 34: 1257-1262.
87. Nautiyal M, Shaltout HA, Chappell MC, Diz DI. Chronic intracerebroventricular angiotensin-(1-7) infusion, but not AT1 receptor blockade, improves vagal components of the baroreflex function in hypertensive (mRen2)27 transgenic rats. Hypertension 2011; 58: e96 (Abstract).
88. Seyedabadi M, Goodchild AK, Pilowsky PM. Differential role of kinases in brain stem of hypertensive and normotensive rats. Hypertension 2001; 38: 1087-1092.
89. Logan EM, Aileru AA, Shaltout HA, Averill DB, Diz DI. The functional role of PI3K in maintenance of blood pressure and baroreflex suppression in (mRen2)27 and mRen2. Lewis rat. J Cardiovasc Pharmacol 2011; 58: 367-373.
90. Grobe JL, Grobe CL, Beltz TG, Westphal SG, Morgan DA, Xu D, de Lange WJ, Li H, Sakai K, Thedens DR, Cassis LA, Rahmouni K, Mark AL, Johnson AK, Sigmund CD. The brain Renin-angiotensin system controls divergent efferent mechanisms to regulate fluid and energy balance. Cell Metab 2010; 12: 431-442.
91. Schinke M, Baltatu O, Bohm M, Peters J, Rascher W, Bricca G, Lippoldt A, Ganten D, Bader M. Blood pressure reduction and diabetes insipidus in transgenic rats deficient in brain angiotensinogen. Proc Natl Acad Sci USA 1999; 96: 3975-3980.
92. Stornetta RL, Hawelu-Johnson CL, Guyenet PG, Lynch KR. Astrocytes synthesize angiotensinogen in brain. Science 1988; 242: 1444-1446.
93. Vinsant S, Chappell MC, Ferrario CM, Ganten D, Diz DI. Low glial angiotensinogen is not associated with deficits in angiotensin peptides in neuronal pathways in transgenic ASrAogen rats. FASEB J 2005; 19: A1188 (Abstract).
94. Baltatu O, Janssen BJ, Bricca G, Plehm R, Monti J, Ganten D, Bader M. Alterations in blood pressure and heart rate variability in transgenic rats with low brain angiotensinogen. Hypertension 2001; 37(2 Part 2): 408-413.
95. Sakima A, Averill DB, Kasper SO, Jackson L, Ganten D, Ferrario CM, Gallagher PE, Diz DI. Baroreceptor reflex regulation in anesthetized transgenic rats with low glia-derived angiotensinogen. Am J Physiol Heart Circ Physiol 2007; 292: H1412-H1419.
96. Caligiorne SM, Silva AQ, Fontes MA, Silva JR, Baltatu O, Bader M, Santos RA, Campagnole-Santos MJ. Baroreflex control of heart rate and renal sympathetic nerve activity in rats with low brain angiotensinogen. Neuropeptides 2008; 42: 159-168.
97. Arnold AC, Sakima A, Ganten D, Ferrario CM, Diz DI. Modulation of reflex function by endogenous angiotensins in older transgenic rats with low glial angiotensinogen. Hypertension 2008; 51: 1326-1331.
98. Sakai K, Chapleau MW, Morimoto S, Cassell MD, Sigmund CD. Differential modulation of baroreflex control of heart rate by neuron-vs. glia-derived angiotensin II. Physiol Genomics 2004; 20: 66-72.
99. Bonini JS, Bevilaqua LR, Zinn CG, Kerr DS, Medina JH, Izquierdo I, Cammarota M. Angiotensin II disrupts inhibitory avoidance memory retrieval. Horm Behav 2006; 50: 308-313.
100. Carter CS, Cesari M, Ambrosius WT, Hu N, Diz D, Oden S, Sonntag WE, Pahor M. Angiotensin-converting enzyme inhibition, body composition, and physical performance in aged rats. J Gerontol A Biol Sci Med Sci 2004; 59: 416-423.
101. de Cavanagh EM, Inserra F, Ferder L. Angiotensin II blockade: a strategy to slow ageing by protecting mitochondria? Cardiovasc Res 2011; 89: 31-40.
102. Sink KM, Leng X, Williamson J, Kritchevsky SB, Yaffe K, Kuller L, Yasar S, Atkinson H, Robbins M, Psaty B, Goff Jr DC. Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study. Arch Intern Med 2009; 169: 1195-1202.
103. Labandeira-Garcia JL, Rodriguez-Pallares J, Villar-Cheda B, Rodriguez-Perez AI, Garrido-Gil P, Guerra MJ. Aging, Angiotensin system and dopaminergic degeneration in the substantia nigra. Aging Dis 2011; 2: 257-274.
104. Wright JW, Harding JW. The brain RAS and Alzheimer's disease. Exp Neurol 2010; 223: 326-333.
105. Elmquist JK, Ahima RS, Maratos-Flier E, Flier JS, Saper CB. Leptin activates neurons in ventrobasal hypothalamus and brainstem. Endocrinology 1997; 138: 839-842.
106. Porte Jr. D, Baskin DG, Schwartz MW. Leptin and insulin action in the central nervous system. Nutr Rev 2002; 60(10 Pt 2): S20-S29.
107. Kasper SO, Ferrario CM, Ganten D, Diz DI. Rats with low brain angiotensinogen do not exhibit insulin resistance during early aging. Endocrine 2006; 30: 167-174.
108. Dietrich MO, Spuch C, Antequera D, Rodal I, de Yebenes JG, Molina JA, Bermejo F, Carro E. Megalin mediates the transport of leptin across the blood-CSF barrier. Neurobiol Aging 2008; 29: 902-912.
109. Koren S, Fantus IG. Inhibition of the protein tyrosine phosphatase PTP1B: potential therapy for obesity, insulin resistance and type-2 diabetes mellitus. Best Pract Res Clin Endocrinol Metab 2007; 21: 621-640.
110. Morrison CD, White CL, Wang Z, Lee SY, Lawrence DS, Cefalu WT, Zhang ZY, Gettys TW. Increased hypothalamic protein tyrosine phosphatase 1B contributes to leptin resistance with age. Endocrinology 2007; 148: 433-440.
111. Monti J, Schinke M, Bohm M, Ganten D, Bader M, Bricca G. Glial angiotensinogen regulates brain angiotensin II receptors in transgenic rats TGR(ASrAOGEN). Am J Physiol Regul Integr Comp Physiol 2001; 280: R233-R240.
112. Kasper SO, Ferrario CM, Ganten D, Diz DI. Central depletion of angiotensinogen is associated with elevated AT1 receptors in the SFO and PVN. Neurotox Res 2004; 6: 259-265.
113. Couto AS, Baltatu O, Santos RA, Ganten D, Bader M, Campagnole-Santos MJ. Differential effects of angiotensin II and angiotensin-(1-7) at the nucleus tractus solitarii of transgenic rats with low brain angiotensinogen. J Hypertens 2002; 20: 919-925.
114. Arnold AC, Shaltout HA, Gallagher PE, Diz DI. Leptin impairs cardiovagal baroreflex function at the level of the solitary tract nucleus. Hypertension 2009; 54: 1001-1008.
115. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007; 292: C82-C97.
116. Rahmouni K, Haynes WG, Mark AL. Cardiovascular and sympathetic effects of leptin. Curr Hypertens Rep 2002; 4: 119-125.
117. Mark AL, Agassandian K, Morgan DA, Liu X, Cassell MD, Rahmouni K. Leptin signaling in the nucleus tractus solitarii increases sympathetic nerve activity to the kidney. Hypertension 2009; 53: 375-380.
118. Kim S, Whelan J, Claycombe K, Reath DB, Moustaid-Moussa N. Angiotensin II increases leptin secretion by 3T3-L1 and human adipocytes via a prostaglandinindependent mechanism. J Nutr 2002; 132: 1135-1140.
119. Cassis LA, English VL, Bharadwaj K, Boustany CM. Differential effects of local versus systemic angiotensin II in the regulation of leptin release from adipocytes. Endocrinology 2004; 145: 169-174.
120. Hilzendeger AM, Morais RL, Todiras M, Plehm R, da Costa GA, Qadri F, Araujo RC, Gross V, Nakaie CR, Casarini DE, Carmona AK, Bader M, Pesquero JB. Leptin regulates ACE activity in mice. J Mol Med (Berl) 2010; 88: 899-907.
121. Koh KK. Distinct metabolic effects of different classes of antihypertensive drugs. Hypertension 2009; 53: e26.
122. Fogari R, Derosa G, Zoppi A, Rinaldi A, Lazzari P, Fogari E, Mugellini A, Preti P. Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. Hypertens Res 2005; 28: 209-214.
123. Hilzendeger AM, Morgan DA, Brooks L, Dellsperger D, Liu X, Grobe JL, Rahmouni K, Sigmund CD, Mark ALA. Brain leptin-renin angiotensin system interaction in the regulation of sympathetic nerve activity. Am J Physiol Heart Circ Physiol 2012; 303: H197-H206.
124. Arnold AC, Diz DI. Endogenous leptin within the solitary tract nucleus contributes to age-related baroreflex suppression in older anesthetized sprague-dawley rats Hypertension 2010; 56: e72 (Abstract).